US equities |
MU $989.04 ▼-3.88% META $742.96 ▲+3.38% NVDA $226.32 ▼-1.29% SNDK $1,487.33 ▼-5.97% SPCX $163.42 ▲+0.52% MSFT $541.15 ▲+1.14% AMD $594.24 ▼-2.28% AAPL $340.97 ▲+1.29%
FinancialContent

Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

17.33 -0.17 (-0.97%)
Delayed Quote Updated: 4:00 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicara Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript ↗
Cash runway extends to 2029 as ficerafusp alfa advances toward interim analysis. 
Via The Motley Fool
Topics Earnings
News headline image
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Results Highlight Clinical Progress as EPS Misses Estimates ↗
Via Chartmill
News headline image
Bicara Therapeutics Q2 Earnings Call Highlights ↗
Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of... 
Via MarketBeat
Topics Earnings
News headline image
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
From Bicara Therapeutics Inc.
Via GlobeNewswire
Top movers in Friday's after hours session ↗
Via Chartmill
News headline image
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? ↗
This Boston-based biotech, focused on bifunctional antibody therapies for cancer, just reported a notable insider sale in recent filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara (BCAX) Q4 2025 Earnings Transcript ↗
Bicara (BCAX) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer ↗
Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the... 
Via MarketBeat
News headline image
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data ↗
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development... 
Via MarketBeat
News headline image
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara (BCAX) Q1 2026 Earnings Transcript ↗
Bicara (BCAX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Bicara Therapeutics Q1 Earnings Call Highlights ↗
Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while... 
Via MarketBeat
Topics Earnings
News headline image
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 ↗
This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider sale during active clinical development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Bicara Therapeutics Inc.
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? ↗
This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder. ↗
This Boston biotech innovator in bifunctional cancer therapies reported a notable insider sale, according to recent filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
From Bicara Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >